Pharmaceuticals News and Research

RSS

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.

23 Nov 2009

Librax AG version launched by Oceanside Pharmaceuticals

Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International, today announced that it has now launched chlordiazepoxide hydrochloride and clidinium bromide, an authorized generic (AG) version of Librax®. Oceanside has received its first orders and expects to be a significant player in the Librax® generic market.

23 Nov 2009

Receptos raises $25 million through Series A financing

Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. The company is focused on identifying and developing best- and first-in-class GPCR therapeutic candidates through information-driven drug discovery, including GPCR structure. Investors include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.

23 Nov 2009

Bio-Quant to be acquired by NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.

23 Nov 2009

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

23 Nov 2009

RXi Pharmaceuticals receives prestigious Innovation of the Year Award

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan’s 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches.

23 Nov 2009

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.

23 Nov 2009

Spectrum Pharmaceuticals, Handok Pharmaceuticals sign collaboration agreement

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.

23 Nov 2009

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.

23 Nov 2009

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

Medical students and biomedical scientists to attend 8th World Congress on Trauma, Shock, Inflammation and Sepsis

The 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010 – will take place from March 9th to13th 2010 in the Auditorium Tract of the Ludwig-Maximilians-University, Campus Grosshadern, in Munich/Germany.

23 Nov 2009

A.P. Pharma regains compliance with shareholders’ equity requirement for continued listing on Nasdaq Capital Market

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on November 19, 2009, the Company received notice from the Nasdaq Listing Qualifications Panel that it has regained compliance with the shareholders’ equity requirement for continued listing on the Nasdaq Capital Market.

23 Nov 2009

Millipore completes acquisition of the remaining 60% ownership of its joint-venture in India

Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today announced it has acquired the remaining 60 percent ownership of its joint-venture in India, Millipore India Pvt. Ltd. The new subsidiary will enable Millipore to invest in initiatives that will drive growth and expand its leadership in India’s thriving life science market.

23 Nov 2009

Initiation of Phase I/IIa clinical trial of IL-7 announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa clinical trial of IL-7 in support of tumor lysate/KLH pulsed dendritic cell vaccines in a pilot study of tumor vaccination in patients with metastatic or recurrent pediatric solid tumors and altered T cell homeostasis, including patients with Ewing’s sarcoma family of tumors (ESFT), rhabdomyosarcoma, neuroblastoma, synovial cell sarcoma, desmoplastic small round cell tumor, undifferentiated sarcoma, and embryonal sarcoma.

23 Nov 2009

Experts to discuss the patented chemical imaging technology at DDL 20 meeting

In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.

23 Nov 2009

ASTMH symposium illustrates the need to generate new medicines for infectious diseases

An urgent need for new medicines to treat neglected infectious diseases in the developing world has prompted a growing number of collaborations among academic researchers, non-profit product development partnerships (PDPs), and pharmaceutical and biotechnology companies.

23 Nov 2009

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

Researchers are invited to contribute their abstracts to the World Congress on Osteoporosis 2010 (IOF WCO - ECCEO10), the largest global meeting devoted to all aspects of osteoporosis and osteoarthritis research and patient care. The Congress will be held in Florence, Italy from May 5-8, 2010.

21 Nov 2009

USGS researchers examine PAHs and PCBs sources in urban environment

Toxic dust: Toxins in coal-tar-based sealcoats in parking lots may be the culprit in contaminated house dust, according to a USGS study. PAHs - or polycyclic aromatic hydrocarbons - are large molecules found in oil, coal and tar deposits, and can have toxic effects.

21 Nov 2009

Ironwood Pharmaceuticals initiates public offering of shares, files registration statement with SEC

Ironwood Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

21 Nov 2009

Zoladex consumers entitled to treble damages, Court rules

The United States Court of Appeals for the First Circuit upheld an earlier District Court ruling yesterday, approving a settlement in the long-running Average Wholesale Price (AWP) pharmaceutical litigation against AstraZeneca Pharmaceuticals ( AZN).

21 Nov 2009

Pharmaceuticals News and Research

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Librax AG version launched by Oceanside Pharmaceuticals

Receptos raises $25 million through Series A financing

Bio-Quant to be acquired by NexMed

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

RXi Pharmaceuticals receives prestigious Innovation of the Year Award

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Spectrum Pharmaceuticals, Handok Pharmaceuticals sign collaboration agreement

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical announces results of NGX426 clinical trial

Medical students and biomedical scientists to attend 8th World Congress on Trauma, Shock, Inflammation and Sepsis

A.P. Pharma regains compliance with shareholders’ equity requirement for continued listing on Nasdaq Capital Market

Millipore completes acquisition of the remaining 60% ownership of its joint-venture in India

Initiation of Phase I/IIa clinical trial of IL-7 announced

Experts to discuss the patented chemical imaging technology at DDL 20 meeting

ASTMH symposium illustrates the need to generate new medicines for infectious diseases

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

USGS researchers examine PAHs and PCBs sources in urban environment

Ironwood Pharmaceuticals initiates public offering of shares, files registration statement with SEC

Zoladex consumers entitled to treble damages, Court rules

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring